Anskar Y.H. Leung is currently a clinical Professor in the Department of Medicine, The University of Hong Kong. He is also the Assistant Dean (Platform Technologies) of LKS Faculty of Medicine. He graduated in 1996 with M.B.,Ch.B. (Hons) and Ph.D. from the Chinese University of Hong Kong and joined the University of Hong Kong as clinical assistant Professor in 1999. He obtained his specialist qualification in Haematology and Haematological Oncology in 2003 and was promoted to Associate Professor and Professor in 2007 and 2012. He has published more than 120 peer reviewed articles including Nature, Blood, Leukemia His research focused on the study of hematopoiesis under normal and neoplastic conditions. In particular, he made use of the zebrafish model to examine the regulatory mechanisms of hematopoiesis in a developmental context and revealed the hitherto undescribed role of methionine aminopeptidase, aldehyde dehydrogenase (ALDH) and Janus kinase 2a (jak2a) in zebrafish definitive hematopoietic stem cells (HSC) and erythropoietic development. These studies not only provided important mechanistic insights to the regulation of hematopoiesis during embryonic development but also platforms for evaluating potential therapeutic agents targeting aminopeptidase and JAK/STAT pathways in the treatment of acute myeloid leukemia (AML). Another research area is the study of chemo-resistance in AML, with particular reference to those subtypes carrying internal tandem duplication (ITD) of Fms-Like Tyrosine Kinase 3 (FLT-3) and expressing high level of aldehyde dehydrogenase (ALDH) and their relevance to the putative leukemia initiating cells (LIC). Based on these studies, clinical trials of therapy targeting FLT3-ITD and ALDH are now in progress with a view to improve the treatment outcome of these